WHITEHOUSE STATION, N.J.—Increasing generic competition and pricing pressures united two more of the world’s largest pharmaceutical players this week, as Merck & Co. announced on Monday it will buy Schering-Plough in a $41.1 billion stock-and-cash deal that some industry veterans are calling “the mating of dinosaurs.”
Amidst its report of a good first-quarter performance, Sanofi-aventis announced late last month a dramatic makeover of its R&D pipeline, including the abandonment of several late-stage drug programs, and continued its recent acquisition streak with the purchase of an oncology-focused company in California.
If you’ve ever met with a financial planner or investment advisor, then you know that one of the first rules of
investing is diversification, an important risk management technique that ensures there are a variety of assets within a portfolio. As biopharmaceutical
organizations, it is important that we recognize the dire consequences that may result if we ignore this proven strategy.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.